Atovaquone targets STAT3 in ovarian cancer spheroids.

被引：0
|
作者：
Neil, Kayli E. [1 ]
Lacroix, Sarah J. [1 ]
Walker, David F. [1 ]
Liu, Suhu [2 ]
Frank, David A. [2 ]
Walker, Sarah R. [1 ]
机构：
[1] Univ New Hampshire, Durham, NH 03824 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CLINICAL CANCER RESEARCH | 2020年 / 26卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B14
引用
收藏
页码：86 / 87
页数：2
相关论文
共 50 条
  • [21] STAT3 mediates ECM stiffness-dependent progression in ovarian cancer
    Chenchen, Sun
    Xueqian, Qian
    Yahui, Lu
    Yi, Yuan
    Hui, Zhang
    Lanning, Bai
    Min, Cheng
    Yangyang, Han
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2025, 480 (01) : 607 - 620
  • [22] Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent
    Xiang, Michael
    Kim, Haesook
    Ho, Vincent T.
    Walker, Sarah R.
    Bar-Natan, Michal
    Anahtar, Melodi
    Liu, Suhu
    Toniolo, Patricia A.
    Kroll, Yasmin
    Jones, Nichole
    Giaccone, Zachary T.
    Heppler, Lisa N.
    Ye, Darwin Q.
    Marineau, Jason J.
    Shaw, Daniel
    Bradner, James E.
    Blonquist, Traci
    Neuberg, Donna
    Hetz, Claudio
    Stone, Richard M.
    Soiffer, Robert J.
    Frank, David A.
    BLOOD, 2016, 128 (14) : 1845 - 1853
  • [23] Patient-specific evaluation of chemoresistance and tumor recurrence using ovarian cancer stem cell spheroids.
    Raghavan, Shreya
    Mehta, Pooja
    Bregenzer, Michael
    Rashidi, Maria Ward
    Fleck, Elyse
    Tan, Lijun
    McLean, Karen
    Buckanovich, Ronald
    Mehta, Geeta
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 55 - 55
  • [24] WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin
    Yang, Jun
    Li, Nanjing
    Zhao, Xinyu
    Guo, Wenhao
    Wu, Yang
    Nie, Chunlai
    Yuan, Zhu
    BIOCHEMICAL PHARMACOLOGY, 2024, 221
  • [25] STAT3: Key targets of growth-promoting receptor positive breast cancer
    Jiang, Rui-yuan
    Zhu, Jia-yu
    Zhang, Huan-ping
    Yu, Yuan
    Dong, Zhi-xin
    Zhou, Huan-huan
    Wang, Xiaojia
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [26] Targeting STAT3 and STAT5 in Cancer
    de Araujo, Elvin D.
    Keseru, Gyorgy M.
    Gunning, Patrick T.
    Moriggl, Richard
    CANCERS, 2020, 12 (08)
  • [27] Onionin A inhibits ovarian cancer progression via STAT3 pathway inactivation of ovarian cancer cells and macrophages in cancer microenvironment
    Tsuboki, J.
    Fujiwara, Y.
    Takaishi, K.
    Saito, F.
    Motohara, T.
    Sakaguchi, I.
    Komohara, Y.
    Tashiro, H.
    Takeya, M.
    Katabuchi, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 847 - 847
  • [28] Activation of signal transducer and activator of transcription 3 (STAT3) in ovarian cancer: The hypoxic implications
    McCann, G.
    Tierney, B.
    Sudhakar, M.
    Cohn, D.
    Karuppaiyah, S.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S144 - S145
  • [29] Activation of Signal Transducer and Activator of Transcription 3 (STAT3) in ovarian cancer: The hypoxic implications
    McCann, Georgia A.
    Naidu, Shan
    Tierney, Brent J.
    Sudhakar, Meryl
    Cohn, David E.
    Selvendiran, Karuppaiyah
    CANCER RESEARCH, 2012, 72
  • [30] Role of Nrf2, STAT3, and Src as Molecular Targets for Cancer Chemoprevention
    Ahsan, Haseeb
    Ul Islam, Salman
    Ahmed, Muhammad Bilal
    Lee, Young Sup
    PHARMACEUTICS, 2022, 14 (09)
12345